Fed. Circ. Axes Bayer ED Drug Patent, Reversing Lower Court

Law360, New York (November 1, 2017, 10:51 PM EDT) -- The Federal Circuit ruled Wednesday that a Bayer patent on the erectile dysfunction drug Staxyn is invalid as obvious, handing a win to generics maker Teva with a strongly worded finding that a Delaware federal judge “clearly erred” when he found that the patent was not invalid.

The appeals court found fault with just about every aspect of a decision that U.S. District Judge Gregory M. Sleet issued after a six-day bench trial, in which he held that Watson Laboratories Inc., now owned by Teva Pharmaceutical...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Bayer Pharma AG v. Watson Laboratories, Inc.


Case Number

16-2169

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

June 2, 2016

Law Firms

Companies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.